Compare VZLA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VZLA | ANAB |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2017 |
| Metric | VZLA | ANAB |
|---|---|---|
| Price | $6.12 | $45.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $7.00 | ★ $58.09 |
| AVG Volume (30 Days) | ★ 7.0M | 542.0K |
| Earning Date | 12-12-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $169,467,000.00 |
| Revenue This Year | N/A | $135.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 196.42 |
| 52 Week Low | $1.69 | $12.21 |
| 52 Week High | $6.16 | $52.47 |
| Indicator | VZLA | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 66.02 | 50.32 |
| Support Level | $5.71 | $42.50 |
| Resistance Level | $6.08 | $50.50 |
| Average True Range (ATR) | 0.26 | 3.18 |
| MACD | 0.01 | -0.30 |
| Stochastic Oscillator | 98.11 | 37.92 |
Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).